{"id":"cgt9486-plus-sunitinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Gastrointestinal toxicity"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hemorrhage"},{"rate":null,"effect":"Fluid retention"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:48:55.724639","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CGT9486 selectively inhibits FLT3 (Fms-like tyrosine kinase 3), a key driver mutation in acute myeloid leukemia, while sunitinib provides broader tyrosine kinase inhibition targeting PDGFR, KIT, and other kinases. The combination aims to overcome resistance mechanisms and improve efficacy in FLT3-mutant AML.","oneSentence":"CGT9486 is a selective FLT3 inhibitor combined with sunitinib, a multi-targeted tyrosine kinase inhibitor, to block FLT3 and PDGFR signaling in acute myeloid leukemia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:26.095Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia with FLT3 mutations"}]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT05208047","phase":"PHASE3","title":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cogent Biosciences, Inc.","startDate":"2022-04-14","conditions":"Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer","enrollment":442},{"nctId":"NCT02401815","phase":"PHASE1, PHASE2","title":"CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Cogent Biosciences, Inc.","startDate":"2015-03-06","conditions":"Gastrointestinal Stromal Tumors","enrollment":51}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CGT9486 plus sunitinib","genericName":"CGT9486 plus sunitinib","companyName":"Cogent Biosciences, Inc.","companyId":"cogent-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CGT9486 is a small molecule being studied in combination with sunitinib for the treatment of gastrointestinal stromal tumors and metastatic cancer. The study, NCT02401815, is a Phase 1b and 2a trial assessing the safety and pharmacokinetics of CGT9486 as a single agent and in combination with sunitinib.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}